To consider and approve the un-audited financial results of the Company for quarter ended June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prevest Denpro's Board approved unaudited standalone and consolidated results for Q1FY26 (quarter ended June 30, 2025). Standalone revenue from operations rose to ₹1,572.27 lakh from ₹1,334.24 lakh a year ago, while net profit jumped to ₹463.42 lakh from ₹365.14 lakh, a YoY growth of about 27%. Profit before tax grew to ₹621.38 lakh from ₹487.46 lakh. EPS stood at ₹3.86 versus ₹3.84 earlier. On a consolidated basis, revenue was ₹1,576.63 lakh and net profit was ₹440.54 lakh. The Board also recommended a final dividend of ₹1 per share (10%) for FY25 and approved a proposal to migrate the company's equity shares from the BSE SME Platform to the BSE Main Board, subject to shareholder and BSE approval.
Strong earnings growth in Q1, with PAT up nearly 27% YoY, signals healthy operational momentum and should be viewed positively by shareholders. The proposed migration to the Main Board could improve liquidity and attract a wider investor base, while the 10% dividend offers modest income.